Navigation Links
Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
Date:10/11/2007

BERKELEY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: SPDU), today announced results from a Phase 1a clinical study of CD-NP, Nile's selective NPR-B agonist being developed for the treatment of heart failure. The results of this study will be included in the Company's presentation today at the BIO Investor Forum in San Francisco, CA.

"The development of a peptide that has natriuretic and renal effects, with relatively little effect on blood pressure, is a potentially important achievement. The results of this trial in healthy volunteers have confirmed some of the hypotheses developed during the pre-clinical studies. We were particularly interested to see a clear, dose dependent increase in cGMP, which suggests the molecule activates the NPR receptors." commented Dr. Barrie Massie, Professor of Medicine, University of California, San Francisco, Chief, Cardiology Section, San Francisco VA Hospital, and member of Nile's scientific advisory board.

Study Design

The Phase 1a study was conducted to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of various doses of CD-NP compared to placebo over a four-hour infusion in 22 healthy volunteers. The study evaluated several pharmacodynamic variables which may translate into safety and efficacy in the heart failure population. Nile measured the effect of CD-NP on systemic blood pressure, urinary flow rate, urinary sodium excretion, serum potassium, renal function and cGMP, a secondary messenger of the target receptor and indicator of in-vivo activity.

Study Results

CD-NP was well tolerated with no serious adverse events and all subjects completed the four-hour infusion of placebo, 10, 17.5 or 25 ng/kg/min of CD-NP.

With respect to clinical and biomarker assessments, CD-NP (placebo, 10, 17.5 and 25 ng/kg/min) increased urine flow rate versus baseline (125%, 53%, 30% and 230% average change, respectively), incre
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
(Date:12/24/2014)... CHENGDU, China, Dec. 24, 2014 /PRNewswire/  -- Tianyin ... a pharmaceutical company that specializes in the patented ... and active pharmaceutical ingredients (API) released unaudited preliminary ... year 2015. Fiscal Year 2015 Ended ... was $9.7 million compared with $14.7 million in ...
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... Technologies, Incorporated (IDEV), an innovative leader in the development ... another step in the implementation of its strategy to ... vascular disease with the addition of two longer stents ... the newly introduced 180mm and 200mm stents occurred in ...
... Shionogi-ViiV Healthcare LLC today announced the start ... once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 (,572). The ... includes two studies (SPRING-2 and SAILING) that will ... but integrase-naive patients. "Progression of ...
Cached Medicine Technology:IDEV Technologies Launches Additional Products in Europe 2Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor 2Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor 3Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor 4Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor 5
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience ... business has introduced its new collection of 2015 prom ... The new prom outfits are guaranteed to contain the ... are specially designed for 2015. Anyone who wants to ... its website before Jan. 26, 2015, the deadline of ...
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
(Date:12/24/2014)... 25, 2014 Over 700 toys, that’s ... local communities. That is 700 smiling little faces this ... Additionally over $6000 in monetary donations was given to ... of the expenses they incur through the year. Some ... A Child's Haven , Shrine's Children's Hospitals, Toys ...
(Date:12/24/2014)... York (PRWEB) December 24, 2014 Risperdal ... in a mass tort litigation currently underway in Pennsylvania’s ... As of December 24, 2014, court documents indicate ... on behalf of individuals who developed gynecomastia (male breast ... Data from the Court indicates that this represents an ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4
... CRT replacements for MRI, CT, US, NM, X-ray, ... is now available from Medical Displays for Less. ... equipment ROI and lower replacement costs with new ... to adapt and display the signals from GE, ...
... also air on the Big Ten NetworkUNIVERSITY PARK, Pa., May ... "Emotionless warriors" and thought scans of detainees may not be ... ethical ramifications of these innovations? Find out by watching the ... State . This new series, hosted ...
... ARLINGTON, Va., May 19 The National Alliance ... "Exemplary Psychiatrists" at the American Psychiatric Association (APA) ... to honor 41 psychiatrists from across the country ... mental illness," said NAMI executive director Michael Fitzpatrick. ...
... , , TUESDAY, May 19 (HealthDay News) -- A mother,s ... own health but on the respiratory health of her ... at an increased risk of asthma if the mother ... the department of prevention and health services research at ...
... now available online to read, share, or purchaseNEW ... ), a global leader in electronic content ... of Physicians (ACP) has launched its e-book portal ... easy-to-implement, cost-effective, self-service solution that allows publishers to ...
... Present Clinical Data at, ... Upcoming Scientific Meeting -,LAVAL, QC, May ... ) today announced the publication of Extended Release Trazodone in Major ... issue of the journal Psychiatry (Edgemont) (Volume 6, Number 5) ( ...
Cached Medicine News:Health News:Universal CRT Replacement Gives New Life to Medical Equipment with Analog Video 2Health News:Universal CRT Replacement Gives New Life to Medical Equipment with Analog Video 3Health News:WPSU Debuts New Series; 1st Show Tackles Neuroscience and the Military 2Health News:NAMI Applauds America's Exemplary Psychiatrists 2Health News:NAMI Applauds America's Exemplary Psychiatrists 3Health News:Overweight Moms More Likely to Have Asthmatic Kids 2Health News:Overweight Moms More Likely to Have Asthmatic Kids 3Health News:American College of Physicians Chooses iPublishCentral to Launch its e-Book Strategy 2Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 2Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 3Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 4
... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
... Meniscal Stapler XLS consists of a resorbable ... the staple. The staple is used in ... The staple is made of a resorbable ... and glycolic acids. Polylactic/polyglycolic acid copolymer degrades ...
... BTA stat Test is an ... qualitative detection of bladder tumor ... with bladder cancer. This test ... aid in the management of ...
... in a bottle becomes preservative-free on ... into oxygen and water on eye ... with mild to moderate dryness or ... treatment. Now you can have the ...
Medicine Products: